# Study the Effect of Niacin on Lipoprotein (a) Concentration and Hyperphosphatemia in Hemodialysis Patients

> **NCT06406140** · PHASE2,PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Al-Azhar University** · enrollment: 50 (estimated)

## Conditions studied

- End-stage Renal Disease

## Interventions

- **DRUG:** Niacin tablets 500 mg

## Key facts

- **NCT ID:** NCT06406140
- **Lead sponsor:** Al-Azhar University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-03-15
- **Primary completion:** 2026-01-15
- **Final completion:** 2026-02-15
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06406140

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06406140, "Study the Effect of Niacin on Lipoprotein (a) Concentration and Hyperphosphatemia in Hemodialysis Patients". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06406140. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*